Literature DB >> 16224535

NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.

Edward S Morris1, Kelli P A MacDonald, Vanessa Rowe, Tatjana Banovic, Rachel D Kuns, Alistair L J Don, Helen M Bofinger, Angela C Burman, Stuart D Olver, Norbert Kienzle, Steven A Porcelli, Daniel G Pellicci, Dale I Godfrey, Mark J Smyth, Geoffrey R Hill.   

Abstract

NKT cells have pivotal roles in immune regulation and tumor immunosurveillance. We report that the G-CSF and FMS-like tyrosine kinase 3 ligand (Flt-3L) chimeric cytokine, progenipoietin-1, markedly expands the splenic and hepatic NKT cell population and enhances functional responses to alpha-galactosylceramide. In a murine model of allogeneic stem cell transplantation, donor NKT cells promoted host DC activation and enhanced perforin-restricted CD8+ T cell cytotoxicity against host-type antigens. Following leukemic challenge, donor treatment with progenipoietin-1 significantly improved overall survival when compared with G-CSF or control, attributable to reduced graft-versus-host disease mortality and paradoxical augmentation of graft-versus-leukemia (GVL) effects. Enhanced cellular cytotoxicity was dependent on donor NKT cells, and leukemia clearance was profoundly impaired in recipients of NKT cell-deficient grafts. Enhanced cytotoxicity and GVL effects were not associated with Flt-3L signaling or effects on DCs but were reproduced by prolonged G-CSF receptor engagement with pegylated G-CSF. Thus, modified G-CSF signaling during stem cell mobilization augments NKT cell-dependent CD8+ cytotoxicity, effectively separating graft-versus-host disease and GVL and greatly expanding the potential applicability of allogeneic stem cell transplantation for the therapy of malignant disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224535      PMCID: PMC1253626          DOI: 10.1172/JCI25249

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

1.  Bioluminescent indicators in living mammals.

Authors:  P R Contag; I N Olomu; D K Stevenson; C H Contag
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

2.  IL-4-producing NK T cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells.

Authors:  M C Leite-De-Moraes; G Moreau; A Arnould; F Machavoine; C Garcia; M Papiernik; M Dy
Journal:  Eur J Immunol       Date:  1998-05       Impact factor: 5.532

3.  Expansion of an unusual population of Gr-1+CD3int cells in the lymph nodes and other peripheral organs of mice carrying the lpr gene.

Authors:  S Honda; K Takeda; J Narita; T Koya; T Kawamura; Y Kuwano; H Watanabe; M Arakawa; T Abo
Journal:  Cell Immunol       Date:  1997-05-01       Impact factor: 4.868

4.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

5.  Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.

Authors:  Y G Yang; J J Sergio; D A Pearson; G L Szot; A Shimizu; M Sykes
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

6.  Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors.

Authors:  J Cui; T Shin; T Kawano; H Sato; E Kondo; I Toura; Y Kaneko; H Koseki; M Kanno; M Taniguchi
Journal:  Science       Date:  1997-11-28       Impact factor: 47.728

7.  IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.

Authors:  M Sykes; V S Abraham; M W Harty; D A Pearson
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

8.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.

Authors:  L Pan; J Delmonte; C K Jalonen; J L Ferrara
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

9.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.

Authors:  N Schmitz; A Bacigalupo; D Hasenclever; A Nagler; E Gluckman; P Clark; P Bourquelot; H Greinix; N Frickhofen; O Ringdén; A Zander; J F Apperley; C Gorin; K Borkett; G Schwab; M Goebel; N H Russell; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  1998-05       Impact factor: 5.483

10.  A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.

Authors:  E Y Denkers; T Scharton-Kersten; S Barbieri; P Caspar; A Sher
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  40 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

Review 2.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

3.  Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Authors:  Angela Shaulov; Simon Yue; Ruojie Wang; Robin M Joyce; Steven P Balk; Haesook T Kim; David E Avigan; Lynne Uhl; Robert Sackstein; Mark A Exley
Journal:  Exp Hematol       Date:  2008-02-08       Impact factor: 3.084

4.  Invariant NKT cells increase drug-induced osteosarcoma cell death.

Authors:  S Fallarini; T Paoletti; N Orsi Battaglini; G Lombardi
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

5.  SOCS3 regulates graft-versus-host disease.

Authors:  Geoffrey R Hill; Rachel D Kuns; Neil C Raffelt; Alistair L J Don; Stuart D Olver; Kate A Markey; Yana A Wilson; Joel Tocker; Warren S Alexander; Andrew D Clouston; Andrew W Roberts; Kelli P A MacDonald
Journal:  Blood       Date:  2010-04-30       Impact factor: 22.113

6.  Pre-transplant donor CD4- invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease.

Authors:  M-T Rubio; M Bouillié; N Bouazza; T Coman; H Trebeden-Nègre; A Gomez; F Suarez; D Sibon; A Brignier; E Paubelle; S Nguyen-Khoc; M Cavazzana; O Lantz; M Mohty; S Urien; O Hermine
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

7.  HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.

Authors:  Nainong Li; Dongchang Zhao; Mark Kirschbaum; Chunyan Zhang; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

8.  Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies.

Authors:  Giuseppina Bonanno; Annabella Procoli; Andrea Mariotti; Maria Corallo; Alessandro Perillo; Silvio Danese; Raimondo De Cristofaro; Giovanni Scambia; Sergio Rutella
Journal:  J Transl Med       Date:  2010-11-09       Impact factor: 5.531

Review 9.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

Review 10.  Mouse models of bone marrow transplantation.

Authors:  Pavan Reddy; Robert Negrin; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.